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Design and Validation of a Bifunctional
Ligand Display System for Receptor Targeting
phage as a strategy to capture phage on fibrinogen or
streptavidin [11] to perform ELISA.
Here we expand this concept by constructing and
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The University of Texas validating a bifunctional phage that displays an integrin
binding motif and a streptavidin binding motif. We alsoM.D. Anderson Cancer Center
1515 Holcombe Boulevard show six potential applications for this dual-display par-
ticle both in vitro and in vivo.Houston, Texas 77030
Results
Summary
Design of the Chimeric Phage Vector
Here we developed a bacteriophage display particle We chose two well-characterized phage clones, RGD-
designed to serve as a bifunctional entity that can 4C and R5C2, to construct a bifunctional display model
target tumors while delivering an agent. We engi- system. RGD-4C phage displays on pIII the double-
neered a chimera phage vector containing a pIII-dis- cyclic CDCRGDCFC peptide that targets v integrins.
played v integrins-targeting moiety and a pVIII-dis- This peptide contains an embedded Arg-Gly-Asp (RGD)
played streptavidin binding adaptor moiety. By using motif found in several extracellular matrix proteins
the chimeric phage particle, targeting of v integrins [12] and allows targeting of tumor-related angiogenic
on cells in culture and tumor-related blood vessels blood vessels [13]. R5C2 phage display the cyclic
was shown through different applications, including ANRLCHPQFPCTSHE peptide—isolated by panning an
luminescent quantum dots localization, surface plas- f88-Cys5 phage display library on immobilized streptavi-
mon resonance-based binding detection, and an din—on approximately 150–300 of the 3900 copies of
in vivo tumor model. The strategy validated here will pVIII (NCBI accession #AF246454). The R5C2 peptide
accelerate the discovery and characterization of re- (among other “biotin-like” peptides) contains the strep-
ceptor-ligand binding events in high throughput, and tavidin binding sequence His-Pro-Gln (HPQ), which con-
cell-specific delivery of diagnostics or therapeutics veniently binds streptavidin at a lower affinity than biotin
to organs of choice without the need for chemical (Kd 2–5  108 and 4  1014, respectively) [14, 15]. In
conjugation. view of these features, we hypothesized that incorporat-
ing HPQ onto the pVIII coat of a chimera phage targeted
to a cell surface receptor would enable (1) reversibleIntroduction
coupling of streptavidin-coupled bioconjugates or (2)
immobilization on streptavidin-coated surfaces, beads,Bispecific compounds can be designed for targeted de-
or luminescent quantum dots (Qdots). These functionallivery to cell surface receptors associated with disease;
properties would be incorporated on a single phagehowever, chemical conjugation or coupling of adaptor
particle while preserving the targeting of v integrin-proteins often results in loss of receptor-ligand binding
expressing cells mediated by the pIII-displayed RGD-capability or insoluble products [1]. On the other hand,
4C peptide.filamentous bacteriophage are versatile display sys-
To produce the chimeric phage, we used the vectorstems, and genetic manipulation renders them suitable
fUSE5 and f88, which share a similar genomic backbonebiological reagents [2–7]. A commonly used phage dis-
[2, 5, 8]. We extracted genomic cis-acting elements fromplay vector is the filamentous bacteriophage M-13 and
each plasmid and reassembled them to create a chimeraits derivative fd-tet [8]. Display of peptides and proteins
phage. DNA isolated from RGD-4C (a fUSE5 derivative)has been achieved in five structural capsid proteins (pIII,
and R5C2 (a f88 derivative) phage clones were digested,pVI, pVII, pVIII, and pIX), but many studies use fusions
and fragments with the corresponding cassettes werewith the phage pIII (minor capsid protein) or the pVIII
ligated to create an RGD-4C/R5C2 phage construct(major capsid protein) because they are efficient presen-
(hereafter termed chimera phage) in which pIII and pVIIItation systems [2, 9].
are mapped to their locations (Figure 1A). The resultingDespite extensive knowledge of the bacteriophage
coat is a mosaic displaying wild-type and recombinantlife cycle and biology [2] and existing data to show that
pVIII proteins (Figure 1B).the simultaneous display of ligands on different proteins
can generate a bifunctional phage, such constructs have
been restricted to in vitro applications such as enzyme- Testing the Streptavidin Binding Capacity
linked immunosorbent assay (ELISA). For example, Light of the Chimera Phage
and Lerner have created so called “PhoPhabs” by incor- To test the streptavidin binding properties of the chi-
porating alkaline phosphatase and antibody (Ab) Fab’s mera, we quantified phage binding to streptavidin-
from combinatorial libraries on a filamentous phage [10], coated plates by ELISA using an anti-phage Ab. The
and Bonnycastle et al. have generated a bifunctional chimera phage bound to immobilized streptavidin at
levels similar to those of the parental R5C2 phage. In-
sertless phage (fd-tet) and parental RGD-4C phage did*Correspondence: rpasqual@mdanderson.org
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Figure 1. Bifunctional Chimera Phage Vector
Design and Construction
(A) Scheme of the construction of chimera
phage with homing and adaptor motifs. Repli-
cative forms of the streptavidin binding phage
R5C2, derived from type f88-Cys5 pVIII dis-
play vector, and the v integrin binding phage
RGD-4C, derived from a fUSE5 pIII display
vector, were digested with BamHI and XbaI.
Swapping of functional fragments from each
vector created a chimera phage vector con-
taining pVIII (red) and pIII (blue) fusion peptide
display domains. Tac promoter drives tran-
scription from the recombinant pVIII cassette
(orange triangle). pVIII: major coat protein VIII;
pIII: minor coat protein III; rpVIII: recombinant
pVIII; rpIII: recombinant pIII; TetR: tetracy-
cline resistance element.
(B) Chimera phage particle representation.
The chimera phage displays the targeting
peptides on the pIII minor coat protein and
an adaptor on the pVIII major coat protein.
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show that binding to streptavidin is mediated by recom-
binant pVIII fusion protein containing the HPQ motif.
Unique 8 kDa bands were observed for the chimera
phage and positive control (R5C2 phage), reflecting the
mobility of recombinant pVIII. We found no reactivity for
the control fd-tet and RGD-4C clones (Figure 2C) or
binding for any of the phage clones in the presence of
biotin. Additional reactive bands in this blot represent
nonspecific binding of streptavidin to other phage pro-
teins and/or to contaminating species from the host
bacteria. These data show that the recombinant pVIII
proteins displaying HPQ motifs on the chimera phage
retain their streptavidin binding capacity.
Cell-Surface Integrin Binding Characteristics
of the Chimera Phage
We next evaluated the binding of the RGD-4C motifs
displayed on pIII of the chimera to cells expressing v3
and v5 integrins to establish specificity. pIII is com-
posed of three domains separated by glycine-rich re-
gions. We produced recombinant fusion proteins of do-
main 1 displaying an RGD-4C peptide (pIIID1-RGD-4C)
or no peptide (pIIID1-fd) for competition assays. In the
fUSE5-based vector, pIII displays peptides at the amino
terminus of D1 (pIIID1; Figure 3A) [2, 5]. The pIIID1 presen-
tation system was designed to display peptides in a
“phage-like” context, with the advantage of a substan-
tially lower cost than synthetic peptides. Pilot studies
(data not shown) demonstrated that the pIIID1-presented
recombinant peptides used here were as active as the
corresponding synthetic peptides at equimolar peptide
concentrations.
We showed that pIIID1-RGD-4C recombinant protein
promoted adhesion of KS1767 cells (Figure 3B), which
express v integrins in high levels and resemble the
phenotype of activated endothelial cells [16], whereas
pIIID1-fd did not (Figure 3C). Cell attachment was inhib-
Figure 2. Chimera Phage Binding to Streptavidin ited by the synthetic peptide RGD-4C but not by the
(A) Binding of the chimera phage to streptavidin-coated plates by negative control peptide CRGESP (data not shown).
ELISA. Phage were incubated with streptavidin (white columns) or These data confirm that cell adhesion in this system is
BSA (black columns). An anti-pVIII monoclonal antibody-HRP conju-
specific and RGD dependent. Having shown that thegate was used for detection. Results are mean  SEM of triplicate
recombinant fusion RGD-4C is functional outside of thewells from two independent experiments.
phage context, we tested the capacity of the chimera(B) Biotin inhibition of phage binding. Biotin was incubated with
each phage before the admixture was added to the coated wells. phage to specifically bind to v integrins expressed in
Results are expressed as percent binding of phage alone (set to the cell surface. Phage were incubated with KS1767
100%). Shown are the mean  SEM from triplicate wells. Inhibitions cells, with or without recombinant fusion proteins. Cell-
of R5C2 phage (dashed line) and chimera phage (solid line) were
bound phage were then separated from unbound phagesimilar.
by an aqueous-organic phase separation method [16].(C) Streptavidin blot hybridization of phage resolved by SDS-PAGE.
Chimera and parental RGD-4C phage specifically boundMembranes with the transferred proteins were reacted with HRP-
streptavidin and processed. Unique 8 kDa bands are visible only to cells at levels up to 45-fold of that in the parental
in the phage displaying streptavidin binding motifs. R5C2 clone, which does not bind to v integrins. Mixing
pIIID1-fd fusion protein with phage before incubation with
cells had no effect on phage binding. However, use of
pIIID1-RGD-4C protein resulted in a marked reduction innot show binding above the background level, and none
of the phage clones bound to BSA (Figure 2A). Next, we binding for the chimera and RGD-4C phage; pIIID1-fd had
no effect on the control R5C2 phage (Figure 3D). Weshowed that biotin inhibits the binding of the chimera
and the R5C2 phage to streptavidin in a similar, dose- also tested binding of the chimera to KS1767 cells by
direct immunostaining of cell-bound phage. Phage weredependent manner (Figure 2B). The level of binding of
RGD-4C and fd-tet phage was very low and was not added to cell monolayers and detected by staining with
an anti-phage Ab (Figures 3E–3L). Chimera phage (Fig-affected by biotin (data not shown). Together, these
results demonstrate the specificity of the chimera phage ure 3E) bound to cells in a manner similar to parental
RGD-4C phage (Figure 3F). The pIIID1-RGD-4C fusiontoward streptavidin. We used Western blot analysis to
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protein inhibited binding of these clones (Figures 3G show that the beads were reactive to streptavidin, RGD-
4C phage were added to the cell monolayer and reactedand 3H), whereas pIIID1-fd had no effect (Figures 3I and
3J). Insertless fd-tet phage (Figure 3K) and parental with an anti-phage and a biotinylated secondary Ab.
Streptavidin-coated beads were then added, and markedR5C2 phage (Figure 3L) were not detected when tested
under identical conditions. These data show that binding fluorescence was observed (Figure 4F), validating the
reactivity of RGD-4C phage with cells and the biotinof the chimera tov integrin-expressing cells is mediated
by the RGD-4C motif and is not affected by the introduc- binding activity of the microspheres. R5C2 phage do
not bind to the cells; therefore, no significant fluores-tion of multiple HPQ motifs on pVIII coat proteins.
cence was detected (Figure 4H). Cells incubated with
RGD-4C phage and uncoated beads showed only back-Applications of the Bifunctional Phage In Vitro
Several different in vitro applications were devised. First, ground fluorescence (data not shown).
Fourth, we evaluated the chimera phage in a biosen-we used a cell-overlay assay in which phage were immo-
bilized on a streptavidin-coated plate and subsequently sor (BIAcore) that monitors molecular interactions by
using surface plasmon resonance [18]. The streptavidinv integrin-expressing cells were added. In wells coated
with control phage, only 4%–7% of the added cells ad- binding moiety on the phage surface was used to immo-
bilize a large number of particles on the surface ofhered to the well surface, whereas in wells coated with
the chimera, over 75% of the input was recovered (Fig- a streptavidin-coated sensor chip, and v integrin-
expressing cells were then injected over the phage-ure 4A).
Second, we performed a binding assay in which phage coated surface to detect real-time binding. The sensor
chip was layered with chimera or R5C2 phage, and sur-were incubated with streptavidin-coated magnetic beads
in suspension and magnetically separated. We then face plasmon resonance signals were measured (Figure
4I). The chimera phage-coated channel showed a higheradded v integrin-expressing cells to the phage-coated
beads. After additional magnetic separation, cells were response to the cells than did the R5C2 phage-coated
channel, whereas the control channel coated with strep-plated and monitored after an overnight incubation at
37C. The number of attached cells in wells from the tavidin alone showed only background cell binding lev-
els (data not shown). The on-rate of cell mass buildupchimera-reacted streptavidin beads was much larger
than the number from negative controls including fd-tet on the chip surface for the chimera phage was over
170% that of control R5C2 phage, as calculated fromphage, RGD-4C phage, or beads alone (Figure 4B); R5C2
phage did not promote cell adhesion despite efficient the slope of the log phase in the sensograms. In spite of
some variation related to the ligand (phage) and analytebinding to beads.
Third, we visualized phage binding to v integrin- (cells), the relative effect observed in the experiments
(binding versus no binding) was consistent.expressing cell monolayers by using fluorescent dye-
containing microspheres coated with streptavidin as a Fifth, we targeted a fluorescently labeled phage to
the cell surface by using nanometer-scale Qdots; thephage detection tool. These microspheres are 40 nm in
diameter and fluoresce within the orange-red emission emission spectrum of the crystals has superior optical
properties because it is very narrow and almost indepen-spectrum [17]; such features facilitate imaging applica-
tions because histologic sections generally autofluo- dent of the excitation wavelength, whereas the fluores-
cence is bright and photostable [19, 20]. We created aresce within the green spectrum. Chimera or control
phage were added to cell monolayers and allowed to fluorescently labeled phage by mixing chimera or con-
trol phage with the streptavidin-coated Qdots. The com-bind, followed by addition of streptavidin-coated or fluo-
rescent microspheres without coating (Figures 4C–4H). plex was incubated with adherent KS1767 cells for 2
(Figures 5A, 5C, and 5E) or 24 hr (Figures 5B, 5D, andIn the wells to which the chimera phage were added,
streptavidin beads were detected in high numbers (Fig- 5F). We monitored the cells for phage binding and inter-
nalization by staining with an anti-phage and a fluores-ure 4C). In contrast, we found low levels of binding with
control beads (Figure 4D). Moreover, RGD-4C phage cein isothiocyanate (FITC)-conjugated secondary Ab.
Cell-bound RGD-4C phage could only be detected when(Figure 4E) or fd-tet phage (Figure 4G), which do not bind
streptavidin, showed only background fluorescence. To an anti-phage Ab was used (Figure 5A), whereas the
Figure 3. Validation of Binding of Chimera Phage to Cells Expressing v Integrins
(A) pIII domain 1 (pIIID1) fusion peptide used in binding inhibition studies. A detailed view of the putative structure of the entire pIII protein
including the domain 1 recombinant protein designed in this study is represented.
(B and C) Adhesion of cells expressing v3 and v5 integrins (KS1767) to plates coated with the recombinant fusion proteins displayed on
pIII of the chimera phage (pIIID1-RGD-4C) (B) or the domain 1 construct of the fd-tet fusion protein (pIIID1-fd) (C). KS1767 cells were added and
allowed to adhere, and the wells were rinsed. Shown are phase-contrast images of representative wells from each group. Scale bar, 10 m.
(D) Binding inhibition of streptavidin binding phage R5C2, v integrin binding phage RGD-4C, and bifunctional chimera phage to KS1767 cells.
Phage were reacted with KS1767 cells, separated, and recovered from the mixture by an aqueous-organic phase separation. Inhibitions were
performed with recombinant pIII fusion proteins. Binding of phage only (filled columns), phage plus pIIID1-RGD-4C (hatched columns), and
phage plus pIIID1-fd (empty columns) is shown. Results are expressed as the mean binding of phage to cells relative to R5C2 phage (set to
1)  SEM.
(E–L) Immunofluorescence of phage binding to KS1767 cells. Cell monolayers were overlaid with the chimera (E, G, and I), RGD-4C phage (F,
H, and J), fd-tet phage (K), or R5C2 parental clone (L). To test inhibition, pIIID1-RGD-4C (G and H) or pIIID1-fd (I and J) proteins were added.
Phage were detected with a FITC-labeled anti-phage antibody. Representative results from three independent experiments are shown. Scale
bar, 10 m.
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Figure 4. Binding of the Chimera Phage through Both Displayed Motifs
(A) Cell overlay assay for phage binding to KS1767 cells and streptavidin. Phage were incubated in streptavidin-coated plates, followed by
the addition of cells. After incubation, adherent cells were counted. The relative fraction of cells remaining on the well surface after washings
is presented as a bound/input ratio (left panel), and representative images from each condition are shown (right panels). Assays were performed
in triplicates, with similar results.
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Figure 5. Targeting Qdots-Streptavidin to
Cells
RGD-4C phage (A and B), chimera phage (C
and D), or R5C2 phage (E and F) were reacted
with Qdot 605 streptavidin, and the comixture
was then added to adherent KS1767 cells and
incubated for 2 hr (A, C, and E) or 24 hr (B,
D, and F). Cells incubated for 2 hr with phage
were then stained with anti-phage antibody
and a secondary FITC conjugate and fixed.
Cells incubated for 24 hr with the phage were
stripped of any cell membrane-bound phage
particles and then permeabilized and stained
with anti-phage antibody in a similar manner
and fixed. Each treatment was repeated
twice. Shown are representative images ac-
quired with an epi-fluorescent microscope by
using the UV-blue excitation filter. White
arrows point to cells showing colocalized yel-
low fluorescence. Scale bar, 10 m.
R5C2 clone showed background fluorescence (Figure get cell surface receptors and to be internalized as a
complex into the cytoplasm.5E). As expected, the chimera phage displayed dual
staining with both red and green fluorescence (colocali-
zation evident by yellow; Figure 5C). Cells incubated for Tumor Targeting with Chimera Phage In Vivo
Having shown the viability of using the bifunctional con-24 hr with RGD-4C or chimera phage internalized the
phage, as shown by green (RGD-4C; Figure 5B) and struct in vitro, we set out to develop a targeting applica-
tion in vivo as proof-of-principle for the chimera phage.yellow (chimera phage; Figure 5D). In contrast, cells
incubated with the R5C2 clone displayed only back- We adopted a well-established mouse mammary gland
tumor model [21] to show the efficiency of the bifunc-ground fluorescence (Figure 5F). Heterogeneity of stain-
ing in Figures 5C and 5D may reflect variations in the tional phage in targeting tumors in vivo. EF43.fgf-4 cells,
which are retrovirally infected with the fgf-4 gene, con-chimera phage binding of Qdots and partial masking of
the FITC green fluorescence by the stronger red signal sistently form highly vascularized tumors in immuno-
competent mice [21].of the Qdots. These results establish the capacity of a
phage-Qdot complex to specifically recognize and tar- Mice bearing tumors with 8–10 mm in diameter re-
(B) KS1767 cell capturing by chimera phage. Phage were mixed with streptavidin-coated magnetic beads and allowed to react. After magnetic
separation, cells were mixed with the beads, separated, plated, and quantified by crystal violet staining. Shown are the absorbances after
dye solubilization (lower panel) and phase contrast micrographs of representative wells from each phage group (upper panels).
(C–H) Cell-surface labeling with chimera or control phage. KS1767 cell monolayers were incubated with chimera (C and D), RGD-4C (E and
F), fd-tet (G), or R5C2 phage (H). Subsequently, streptavidin-coated fluorescent beads (C, E, G, and H) or control beads (D) were added and
allowed to react with the phage. For the anti-M13 pVIII antibody cells, incubation with a secondary biotinylated antibody was followed by the
addition of streptavidin-coated microspheres (F). The plate was observed under a fluorescence microscope. Images were acquired by
simultaneously using a red fluorescence filter and a bright light field. Representative images from three independent experiments with duplicate
wells for each test group, with similar results, are shown. Scale bar, 10 m.
(I) Interaction of the chimera phage with KS1767 cells by BIAcore. After 1011 TU/ml of chimera or R5C2 phage were coated onto streptavidin
BIAcore chips at similar levels, chips were subjected to a KS1767 single-cell suspension flow (at 105 cells/ml). Responses were recorded to
saturation. Shown are representative sensograms acquired from the two phage-coated channels normalized to the injection point (time zero).
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Figure 6. In Vivo Targeting of Chimera-Qdot Complex to Tumors
(A) Phage recovered from tissues of mice that received phage/Qdot complexes intravenously. Tumor/control organ homing ratios for different
phage clones are presented.
(B–D) Immunostaining for phage in mice injected with phage/Qdot complexes. Anti-phage antibody reveals strong staining of blood vessels
in the RGD-4C/Qdot-injected mouse (black arrows in [C]) and a larger aggregated pattern for the chimera-Qdot-injected mouse (black arrows
in [D]). Scale bar, 20 m.
(E–J) Fluorescent microscopy of tissues injected with phage/Qdot complexes. Large fluorescent aggregates are present in a tumor from a
mouse injected with the chimera-Qdot complex (E–G), but no signal is present in tumors from RGD-4C/Qdot complex-injected mouse (H–J).
Scale bar, 10 m.
ceived phage clones reacted with Qdots streptavidin accumulation of targeted phage in tumors. This result
was further corroborated by immunohistochemistryintravenously. After perfusion, tumor and control organs
were surgically removed. Brain was chosen as a stan- (Figures 6B–6D), showing substantial RGD-4C and chi-
mera phage localization in the tumor (Figures 6C anddard reference organ because of its low phage tissue
uptake [13, 22]. We found preferential homing of the 6D) and only background staining from fd-tet phage-
injected mice (Figure 6B). Control organs (such as brainRGD-4C and the chimera phage to the tumor (Figure
6A). Specifically, the tumor/control organ (brain) homing and liver) from these mice were stained and showed
similar staining patterns for all three phage (data notratio for fd-tet phage was 6.5, compared with tumor/
control organ homing ratios of 25 for the RGD-4C phage shown).
Qdot signals are particularly challenging to detectand 26 for the chimera phage. These data show a 4-fold
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in vivo; most of the applications described thus far focus not yet been explored in detail, this distribution pattern
suggests that other complexes based on streptavidinon cell imaging in vitro. However, we could easily identify
Qdots targeted to v integrins in the tissues examined. conjugates (e.g., macromolecule-based drug carriers,
liposomes, and polymeric drug delivery systems) mayStrong fluorescence was detected in the tumors of mice
that received the chimera phage-Qdot complex intrave- be targeted and exert their effect in the tumor tissue.
Moreover, while phage particles accumulate in organsnously (Figures 6E–6G) but not in the tumors of mice
that received RGD-4C phage-Qdot or fd-tet phage-Qdot that are part of the reticulo-endothelial system, such as
liver and spleen, receptor-mediated internalization does(Figures 6H–6J). Together, these data show that the
chimera phage-Qdot complex can be targeted to tumors not appear to take place in such sites. This is an aspect
that favors targeted intracellular delivery in this system.in vivo.
Phage display technology is widely available and can
be easily adapted to any biological system studied. After
Discussion identification of a peptide motif or an Ab-phage clone
that interacts specifically with a target molecule, various
Chemical reactions to produce active targeted bioconju- applications can be immediately developed to study and
gates are widely used in a variety of biotechnology appli- target the new molecule. Although other chemical and
cations. Such conjugates consist of an effector bioactive biological targeting strategies may be more suitable in
agent and a targeting-carrier moiety that confers speci- some settings [24], this system may enhance the capa-
ficity of action, increases drug load, or avoids common bilities of monitoring binding and trafficking in cellular
clearance mechanisms [1]. However, several technical assays. Such a simple means of detecting and following
problems can hinder the production of effective targeted phage clones after binding to cellular receptors of inter-
agents. Mild conditions are required to maintain the est would likely enhance our understanding of many
activity of the bioconjugate components (more when newly discovered molecular targets.
activation of the conjugate counterparts is needed), and In summary, the work presented here demonstrates
yield is generally low. Changes in hydrophobicity and that a bifunctional phage can capture or target probes
molecular weight of the resulting conjugate can also to cells expressing receptors of interest while avoiding
result in loss of solubility. These obstacles may either complex chemical conjugations. Targeting beads or Qdots
prevent the production or alter the pharmacologic char- and phage immobilization onto different surfaces—such
acteristics of desired conjugates. as microarray chips, colloidal particles, or various solid
Phage display has been used for antigen-antibody phases—may yield new tools for the discovery and char-
epitope mapping, identification of protein binding sites acterization of molecular targets. Collectively, the exper-
in receptor-ligand interactions, enzyme functional do- iments described extend the concept of bifunctional
main inhibition, cell targeting, and even for direct selec- phage display into several potentially useful research
tion in patients [2–7, 16, 23]. Importantly, methodology and preclinical applications.
for phage ELISA using the appealing concept of bifunc-
tional phage has long been developed [10, 11]. However, Significance
several considerations to bifunctional phage systems
merit further comment. Among them are affinity of the Targeted delivery of agents to tumors may form the
complexes, reduction on the effective density of ligands basis of a new pharmacology that exploits biochemical
of interest, and in vivo stability. As far as affinity of the differences on the surface of cancer cells and of those
complexes, we believe the data presented here provide cells forming tumor-associated blood vessels. How-
sound evidence of the binding capacity of the phage to ever, efficient application of this concept has been
various surfaces. In the settings tested (coated plastic, hindered by the complex chemistry and difficulty in
magnetic beads, BIAcore chips, and Qdots), phage the reliable production of bispecific conjugates. The
bound in a stable, though not always quantifiable, man- proof-of-principle presented here shows that it is pos-
ner. Follow-up comparisons of the chimeric phage con- sible to develop biologically active particles that target
struct to chemically biotinylated RGD-4C phage, al- cell surface receptors. This practical and convenient
though technically challenging, might yield additional modular system may allow easy selection and charac-
data. Despite the considerable reduction on the effective terization of functional protein-protein interactions
density of ligands when phage are used—as phage oc- and their integration with other technologies toward
cupies most of the surface of interest when the particle translational applications.
is immobilized—this approach can still be possible, as
Experimental Proceduresevident from previous reports [10, 11] and from the work
presented here. Still, this important issue must be care-
Generation of a Bifunctional Phage Vectorfully considered when designing experiments and may
To create a chimera phage, unique restriction sites present at similar
limit certain applications. Finally, as to the in vivo stabil- locations in the plasmid DNA of two existing phage were chosen.
ity, indeed, no one has yet conducted a methodical In both, a BamHI site is located about 670 bp downstream from the
pIII gene initiation codon. An XbaI site is located 4 bp downstreamstudy of the integrity of the complex. However, we show
from the initiation codon of the tetracycline (Tet) repressor proteinthat in some cases the stability of the phage-streptavidin
gene. DNA extracted from a fUSE5 vector (clone RGD-4C) [12] andconjugate complex is high enough to allow delivery of
an f88-Cys5 vector (clone R5C2, NCBI accession #AF246454) [25]large complexes to their target site. The dotted pattern
was used to transform MC1061 Escherichia coli. Single colonies
of fluorescence in the tumor for the chimera-Qdot indi- selected on Luria-Bertami (LB) agar plates containing streptomycin
cates stability, at least for a short circulation timeframe. and tetracycline were cultured overnight, and plasmid DNA was
extracted by using a plasmid purification kit (Qiagen, Valencia, CA).Although the nature of the observed aggregates has
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One microgram of DNA from each clone was digested with XbaI K91Kan E. Coli for 1 hr, plated, incubated, and quantified. For immu-
nocytochemical analysis of phage binding, 105 KS1767 cells wereand BamHI restriction endonucleases (Roche, Mannheim, Ger-
many). The digested DNA was resolved on a 0.8% agarose gel, and seeded in a 48-well tissue culture plate and allowed to attach over-
night at 37C. Next, 5  109 phage TU were added to the cells, withthe desired DNA fragments (i.e., a 3925 bp fragment from RGD-4C
plasmid and a 5402 bp fragment from R5C2 plasmid) were extracted or without 400 g of pIIID1 fusion proteins, and incubated for 2 hr
at RT. Bound phage were detected with anti-fd bacteriophage Aband purified using a gel purification kit (Qbiogene, Vista, CA). DNA
fragments were ligated overnight at 16C with T4 DNA ligase (Life (Sigma) and a FITC-conjugated secondary Ab. Cells were then fixed
with PFA and visualized by fluorescence microscopy.Technologies, Grand Island, NY). The ligation product was electro-
porated into MC1061 E. coli and plated on LB-agar plates containing
tetracycline and streptomycin. Restriction digests of plasmid DNA Binding of the Chimera Phage via Both
from multiple colonies were analyzed on E-Gels (Invitrogen, Carls- Peptide Display Systems
bad, CA). Sequences were confirmed by PCR with specific primers. In cell overlay assays, 5  109 TU of phage were incubated on
streptavidin ReactiBind plates (Pierce) for 2 hr at RT and washed
Chimera Phage Binding to Streptavidin with PBST. KS1767 cells were then added in triplicate (104 cells/
Phage from double-insert-positive clones were purified using the well) and incubated for 2 hr, and wells were washed and fixed with
polyethylene glycol-NaCl method [2]. To test the binding of phage PFA. Cells in each group were counted under a phase-contrast
to streptavidin, we used streptavidin high binding capacity plates microscope. For cell capture with magnetic beads, 109 phage TU
(Reacti-Bind, Pierce, Rockford, IL). One billion phage transducing were combined with 10 l (0.1 mg) of Dynabeads M-280 streptavi-
units (TU) in PBS containing 2% bovine serum albumin (BSA) were din-coated beads (Dynal, Oslo, Norway) in binding buffer (5 mM
incubated in triplicate wells for 2 hr at room temperature (RT) and Tris-HCl [pH 7.5], 0.5 mM EDTA, 1 M NaCl) for 90 min at RT and
washed with PBS containing 0.01% Tween-20 (PBST). For inhibition washed three times with binding buffer in an MPC-S magnetic appa-
experiments, biotin (Sigma Chemical Co., St. Louis, MO) was mixed ratus (Dynal). Beads were resuspended in 200 l of PBS, mixed with
with the phage before incubation on the plate. Phage binding was 5 104 cells in PBS containing 2% BSA, agitated for 90 min, washed
measured by ELISA by using a horseradish peroxidase (HRP)/anti- twice, and resuspended in PBS containing 2% BSA. Cells were
M13 monoclonal Ab (mAb) conjugate (Amersham Biosciences, Pis- plated in a 48-well tissue culture plate, incubated overnight at 37C,
cataway, NJ) and developed with 3, 3, 5, 5-tetramethylbenzidine fixed in PFA, and examined under a phase-contrast microscope.
(Calbiochem, La Jolla, CA). Absorbance at 450 nm was determined For quantification, 0.5% crystal violet dye in 20% methanol was
in a plate reader (Bio-Tek Instruments Inc., Winooski, VT). For the added to each well. Wells were washed with water, bound dye was
streptavidin hybridization, 5  109 phage TU were denatured and dissolved in 50 l of 1:1 (v/v) 0.1 M sodium citrate (pH 6.0):methanol,
resolved on a Novex 16% polyacrylamide gel electrophoresis and absorbance at 550 nm was determined.
(PAGE)-tricine (Invitrogen) and transferred to Trans-Blot nitrocellu-
lose membrane (Bio-Rad, Hercules, CA). The membrane was
Cell-Surface Detection of Bound Phageblocked with 3% BSA in Tris-buffered saline containing 0.01%
with Fluorescent BeadsTween-20 and incubated with HRP-conjugated streptavidin (Amer-
KS1767 cells (105 per well in a 48-well plate) were incubated insham Biosciences UK, Buckinghamshire, England) overnight at 4C.
duplicates with 1010 TU of chimera, RGD-4C, R5C2, or fd-tet phageBlots were washed three times with PBST and developed with the
in MEM containing 2% BSA for 2 hr at RT. After washing, 1011enhanced chemiluminescence (ECL) plus reagent (Amersham Bio-
streptavidin-coated or uncoated red-orange fluorescent micro-sciences UK) for 3 min. Membrane was exposed to HyperFilm ECL
spheres (Molecular Probes, Eugene, OR) were added in 200 l offilm (Amersham Biosciences UK) for detection.
BlockAid solution (Molecular Probes) for 2 hr. Cells were washed,
fixed in PFA, and examined under a fluorescence microscope. To
pIIID1 Preparation and Purification validate reactivity of streptavidin on fluorescent beads toward biotin,
The pIIID1 coding regions from insertless fd-tet phage or phage dis- cells were incubated with anti-M13 pVIII mAb (Amersham Biosci-
playing the RGD-4C peptide were amplified directly from phage ence) and a biotinylated secondary Ab (Sigma). Cells were then
DNA through PCR by using the primer sets: 5-CCTTTCTATTCTCA treated with streptavidin-coated beads and evaluated by fluores-
TATGGCCGACGGGGC-3/5-CTCAGAACCGCCACCCTCGAGGCC cence microscopy.
ACC-3 (for RGD-4C), or 5-CGCGAATTCTTATTATTCGCAATTCCT
TTAGTTG-3/5-CTCAGAACCGCCACCCTCGAGGCCACC-3 (for fd-
Surface Plasmon Resonancetet). PCR products were digested with NdeI and XhoI (RGD-4C
Streptavidin-coated chips (BIAcore AB, Uppsala, Sweden) were im-phage) or EcoRI and XhoI (fd-tet phage) and subcloned into the
mobilized with purified 1011 TU/ml of chimera or R5C2 phage inpET21a vector (Novagen, Madison, WI). The constructs were se-
two separate channels by injecting the phage suspension in twoquenced, and the recombinant proteins were expressed in E. coli
consecutive cycles of 20 l/min for 6 min in a biosensor (BIAcoreBL21 DE3 (Novagen). Induced recombinant proteins were purified
AB). Similar signals were achieved. Single-cell suspensions offrom bacterial extracts under native conditions using a Ni2	NTA-
freshly harvested KS1767 cells in PBS were injected over all theagarose column (Qiagen). Protein purity greater than 95% was deter-
channels at 105 cells/ml for 10 min and sensograms recorded. Themined on sodium dodecyl sulfate (SDS)-PAGE. For cell adhesion
on-rates were calculated from the slopes of the log phase in theassays, 48-well plates were coated with pIIID1-RGD-4C, pIIID1-fd or
sensograms. All stages were conducted at 25C. Data acquired werevitronectin (20 g/ml each) and blocked in PBS containing 3% BSA.
processed through software provided by the manufacturer.Human Kaposi’s sarcoma-derived cells (KS1767) were detached
with 2.5 mM PBS-EDTA, resuspended in modified Eagle’s medium
(MEM), and added to the wells (105 cells/well). After 1 hr, unattached Cell Targeting of Qdot-Labeled Chimera Phage
cells were removed by gentle washing, and attached cells were Qdot 605 streptavidin (Quantum Dot, Hayward, CA) was mixed with
fixed in 4% PBS-buffered paraformaldehyde (PFA). Images were chimera, RGD-4C, or R5C2 phage (at 5  109 TU each) in duplicates
acquired on a phase-contrast microscope. and incubated under rotation at RT for 45 min. Each admixture was
added to 105 adherent KS1767 cells in a Lab-Tek II chamber slide
(Nalge Nunc, Naperville, IL) in MEM containing 2% BSA and incu-Testing Phage Binding to Cell Surface Integrins
An established aqueous-organic phase separation method was bated for 2 hr at RT or 24 hr at 37C for the internalization assay.
Cells incubated for 2 hr were washed, incubated with anti-M13 mAbused to assess phage binding [16]. Briefly, 105 human Kaposi’s
sarcoma-derived cells KS1767 were harvested in 2.5 mM PBS-EDTA and anti-mouse IgG FITC conjugate (Sigma), and fixed with PFA.
For the internalization study, cells were washed with 50 mM glycine/and incubated with 109 phage TU in modified Eagle’s medium (MEM)
containing 2% BSA, with or without 400 g of pIIID1 fusion proteins, 500 mM NaCl buffer, fixed with PFA, permeabilized with 0.2% Triton
X-100 solution, blocked with 1% BSA in PBS solution, then incu-for 3 hr at 4C. Cells were loaded on 200 l of 9:1 (v/v) dibutyl
phthalate:cyclohexane (Aldrich Chemical Co., Milwaukee, WI) and bated with anti-M13 mAb and the secondary FITC conjugate, and
fixed again in PFA. Slides were mounted with Mowiol 4-88 (Poly-centrifuged at 4C for 10 min. Pellets were infected with log-phase
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sciences, Eppelheim, Germany), visualized under an epi-fluorescent 9. Gao, C., Mao, S., Kaufmann, G., Wirsching, P., Lerner, R.A., and
Janda, K.D. (2002). A method for the generation of combinatorialmicroscope, and microphotographed by using a UV-blue filter.
antibody libraries using pIX phage display. Proc. Natl. Acad.
Sci. USA 99, 12612–12616.Targeting Phage-Qdot Complexes to Tumors in Mice
10. Light, J., and Lerner, R.A. (1992). Phophabs: antibody-phage-Eight-week-old Balb/C mice were inoculated subcutaneously with
alkaline phosphatase conjugates for one step ELISA’s without105 EF43.fgf-4 cells [21] in the right flank, and tumors were allowed
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